CAMBRIDGE, Mass., Oct. 16, 2019 /PRNewswire/ — SmartPharm Therapeutics, a preclinical-stage pharmaceutical company focused on developing next-generation, non-viral gene therapies for the treatment of rare diseases, today announced that José Trevejo, MD, PhD, Chief Executive Officer, will present at the 2019 BIO Investor Forum on Wednesday, October 23 at 9:00 a.m. PT in San Francisco. You can view a recording of the presentation here:
About SmartPharm Therapeutics
SmartPharm Therapeutics Inc. is a privately held, development-stage pharmaceutical company focused on developing next-generation, non-viral gene therapies for the treatment of serious- and rare diseases with the vision of creating “Biologics from Within.” The Company is currently developing a novel pipeline of non-viral, gene-encoded proteins for the treatment of conditions that require enzyme replacement therapy and tissue restoration. SmartPharm commenced operations in 2018 and is headquartered in Cambridge, MA, USA. For more information, please visit www.smartpharmtx.com.